Listing Kratom As Schedule I Will Impede Research Opportunities
The DEA’s plan to list kratom as a Schedule I controlled substance would make researching the possible opioid substitute much more difficult.
The DEA’s plan to list kratom as a Schedule I controlled substance would make researching the possible opioid substitute much more difficult.
Dr. Roger McIntyre suggests that the clinical relevance of cognitive dysfunction for any individual patient can only be adjudicated on a case-by-case basis.